Nivolumab plus relatlimab and nivolumab plus ipilimumab for patients with advanced renal cell carcinoma: results from the open-label, randomised, phase II FRACTION-RCC trial
Results showed antitumour activity and manageable safety with NIVO + RELA. Findings also support NIVO + IPI as an effective combination regimen in IO-naive patients with aRCC.
Authors
- Harriet M. Kluger (ORCID: https://orcid.org/0000-0002-4932-9873)
- Scott S. Tykodi (ORCID: https://orcid.org/0000-0002-0399-0965)
- Timothy M. Kuzel (ORCID: https://orcid.org/0000-0002-7523-2397)
- B. Escudier
- Sumati Gupta (ORCID: https://orcid.org/0000-0001-6271-0831)
- Prabhu Bhagavatheeswaran
- Sangeeth M. George
- Ruth Perets (ORCID: https://orcid.org/0000-0001-7216-6577)
- Howard Gurney (ORCID: https://orcid.org/0000-0003-0217-5261)
- Edmund Folefac (ORCID: https://orcid.org/0000-0002-8753-2311)
- Chung‐Wei Lee (ORCID: https://orcid.org/0000-0002-3573-2506)
- Wilson H. Miller (ORCID: https://orcid.org/0000-0002-7408-1574)
- Toni K. Choueiri (ORCID: https://orcid.org/0000-0002-9201-3217)
- Elena Verzoni (ORCID: https://orcid.org/0000-0001-9756-6112)
- Heshani Desilva
- U. Vaishampayan
- R.J. Motzer
- Chi‐Hang Lee (ORCID: https://orcid.org/0000-0001-8777-2705)
- Suresh Nair (ORCID: https://orcid.org/0000-0001-7763-9732)
- Vincent Castonguay (ORCID: https://orcid.org/0000-0001-8053-4026)
- Russell K. Pachynski (ORCID: https://orcid.org/0000-0002-8966-7631)
- Yan Wang (ORCID: https://orcid.org/0000-0001-5624-6745)
Institutions
- Rush University Medical Center (US)
- Roswell Park Comprehensive Cancer Center (US)
- Lehigh Valley Hospital-Pocono (US)
- Memorial Sloan Kettering Cancer Center (US)
- Bristol-Myers Squibb (Germany) (DE)
- Washington University in St. Louis (US)
- Rambam Health Care Campus (IL)
- Jewish General Hospital (CA)
- Institut Gustave Roussy (FR)
- Yale Cancer Center (US)
- The Ohio State University Wexner Medical Center (US)
- Fred Hutch Cancer Center (US)
- Bristol-Myers Squibb (United States) (US)
- Michigan Medicine (US)
- Bristol-Myers Squibb (Sweden) (SE)
- Fondazione IRCCS Istituto Nazionale dei Tumori (IT)
- Dana-Farber Brigham Cancer Center (US)
- Université Laval (CA)
- Macquarie University (AU)
Publication Details
- Journal
- ESMO Open
- Published
- 2024-12-01
- DOI
- https://doi.org/10.1016/j.esmoop.2024.104073
- Citations
- 12
- Primary Topic
- Renal cell carcinoma treatment
- Type
- article
- Field-Weighted Citation Impact
- 5.03
Funders
- Bristol-Myers Squibb
- Memorial Sloan-Kettering Cancer Center
- Ono Pharmaceutical